Bone Fixation of Mpact Double Mobility Cup
Etude Prospective, Multicentrique, Non contrôlée, Non randomisée, Ouverte Pour l'évaluation de la Fixation Osseuse d'Une Cupule hémisphérique, le Mpact® Double Mobilité
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Mara Colombo
- Phone Number: +41 91 696 60 60
- Email: colombo@medacta.ch
Study Locations
-
-
France
-
Annecy, France, France, 74000
- Clinique Générale
-
Saint-Etienne, France, France, 42100
- Orthéo - Espace Fauriel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- primary hip replacement
- patients 18 to 80 years old
- patients who accept the follow-up schedule
Exclusion Criteria:
- femoral neck fracture
- patients requiring grafts
- progressive local or systemic infections
- patients presenting muscular deficiency, neuromuscular disease or vascular insufficiency of the involved limb
- patients suffering from diseases that can compromize the recovery to independent mobility
- patients with BMI > 40
- patients with cognitive diseases that can compromize their participation in the study
- patients living in geographical area not allowing the clinical follow-up to be performed
- patients participating in other biomedical research
- patients <18 years old
- patients > 80 years old
- pregnant or breast feeding women
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
implant fixation trough IMAGIKA
Time Frame: 10 years
|
implant fixation trough IMAGIKA
|
10 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Harris Hip Score
Time Frame: preop, 3 months, 1, 2, 5, 10 years
|
Harris Hip Score
|
preop, 3 months, 1, 2, 5, 10 years
|
|
complications
Time Frame: intraop, immediate postop, 3 months, 1, 2, 5, 10 years
|
complications
|
intraop, immediate postop, 3 months, 1, 2, 5, 10 years
|
|
penetration of femoral head in the polyethylene insert trough IMAGIKA
Time Frame: 3 months, 5 and 10 years
|
penetration of femoral head in the polyethylene insert trough IMAGIKA
|
3 months, 5 and 10 years
|
|
implant stability trough standard x-ray
Time Frame: 3 months, 1, 2, 5, 10 years
|
implant stability trough standard x-ray
|
3 months, 1, 2, 5, 10 years
|
|
implant survival trough Kaplan-Meier curve
Time Frame: 3 months, 1, 2, 5, 10 years
|
implant survival trough Kaplan-Meier curve
|
3 months, 1, 2, 5, 10 years
|
|
implant fixation trough IMAGIKA
Time Frame: 3 months and 5 years
|
implant fixation trough IMAGIKA
|
3 months and 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- P01.017.01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.